{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:18:54Z","timestamp":1790014734306,"version":"4.0.1"},"reference-count":222,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 1R01CA255074"],"award-info":[{"award-number":["R01 1R01CA255074"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["R01 CA239694"],"award-info":[{"award-number":["R01 CA239694"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["R01 CA279467"],"award-info":[{"award-number":["R01 CA279467"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["R01 EB034665"],"award-info":[{"award-number":["R01 EB034665"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["R21 CA280238"],"award-info":[{"award-number":["R21 CA280238"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RR200046"],"award-info":[{"award-number":["RR200046"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005984","name":"Dr. Miriam and Sheldon G. Adelson Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005984","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008746","name":"National Cancer Center","doi-asserted-by":"publisher","award":["CA016672"],"award-info":[{"award-number":["CA016672"]}],"id":[{"id":"10.13039\/100008746","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH2210504_BC211174"],"award-info":[{"award-number":["W81XWH2210504_BC211174"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["VC2020-001"],"award-info":[{"award-number":["VC2020-001"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-21-1-0282_OC200482"],"award-info":[{"award-number":["W81XWH-21-1-0282_OC200482"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013140","name":"Colorectal Cancer Alliance","doi-asserted-by":"publisher","award":["1005847"],"award-info":[{"award-number":["1005847"]}],"id":[{"id":"10.13039\/100013140","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U01 CA 281902"],"award-info":[{"award-number":["U01 CA 281902"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.cell.2026.03.035","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T15:03:30Z","timestamp":1776351810000},"page":"2278-2306","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Targeting genomic instability in cancer"],"prefix":"10.1016","volume":"189","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2154-3309","authenticated-orcid":false,"given":"Timothy A.","family":"Yap","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Charles","family":"Manning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puja","family":"Sapra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon B.","family":"Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"O\u2019Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cell.2026.03.035_bib1","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/nature08467","article-title":"The DNA-damage response in human biology and disease","volume":"461","author":"Jackson","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.cell.2026.03.035_bib2","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/nrm2858","article-title":"Genomic instability--an evolving hallmark of cancer","volume":"11","author":"Negrini","year":"2010","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.cell.2026.03.035_bib3","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.molcel.2010.09.019","article-title":"The DNA damage response: making it safe to play with knives","volume":"40","author":"Ciccia","year":"2010","journal-title":"Mol. Cell"},{"key":"10.1016\/j.cell.2026.03.035_bib4","doi-asserted-by":"crossref","first-page":"M57","DOI":"10.1016\/S0962-8924(99)01661-X","article-title":"Genetic instability and darwinian selection in tumours","volume":"9","author":"Cahill","year":"1999","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.cell.2026.03.035_bib5","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1126\/science.959840","article-title":"The Clonal Evolution of Tumor Cell Populations","volume":"194","author":"Nowell","year":"1976","journal-title":"Science"},{"key":"10.1016\/j.cell.2026.03.035_bib6","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hallmarks of cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.cell.2026.03.035_bib7","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.cell.2026.03.035_bib8","volume":"42","author":"Chi","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cell.2026.03.035_bib9","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.cell.2009.02.024","article-title":"Principles of cancer therapy: oncogene and non-oncogene addiction","volume":"136","author":"Luo","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.cell.2026.03.035_bib10","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2021108389","article-title":"Cancer evolution: Darwin and beyond","volume":"40","author":"Vendramin","year":"2021","journal-title":"EMBO J."},{"key":"10.1016\/j.cell.2026.03.035_bib11","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.molcel.2015.10.040","article-title":"Targeting the DNA Damage Response in Cancer","volume":"60","author":"O\u2019Connor","year":"2015","journal-title":"Mol. Cell"},{"key":"10.1016\/j.cell.2026.03.035_bib12","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41571-018-0114-z","article-title":"State-of-the-art strategies for targeting the DNA damage response in cancer","volume":"16","author":"Pili\u00e9","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.cell.2026.03.035_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/or.2025.1527742","article-title":"Historical view of the effects of radiation on cancer cells","volume":"19","author":"Hazout","year":"2025","journal-title":"Oncol. Rev."},{"key":"10.1016\/j.cell.2026.03.035_bib14","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrc2167","article-title":"The resurgence of platinum-based cancer chemotherapy","volume":"7","author":"Kelland","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.cell.2026.03.035_bib15","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.chembiol.2010.04.012","article-title":"DNA topoisomerases and their poisoning by anticancer and antibacterial drugs","volume":"17","author":"Pommier","year":"2010","journal-title":"Chem. Biol."},{"key":"10.1016\/j.cell.2026.03.035_bib16","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.1101\/gad.12.18.2956","article-title":"Recovery from DNA replicational stress is the essential function of the S-phase checkpoint pathway","volume":"12","author":"Desany","year":"1998","journal-title":"Genes Dev."},{"key":"10.1016\/j.cell.2026.03.035_bib17","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1126\/science.1083430","article-title":"Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes","volume":"300","author":"Zou","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.cell.2026.03.035_bib18","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.molonc.2011.07.002","article-title":"Targeting ATR and Chk1 kinases for cancer treatment: a new model for new (and old) drugs","volume":"5","author":"Toledo","year":"2011","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.cell.2026.03.035_bib19","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.cell.2013.10.043","article-title":"ATR Prohibits Replication Catastrophe by Preventing Global Exhaustion of RPA","volume":"155","author":"Toledo","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.cell.2026.03.035_bib20","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1146\/annurev-pathol-012414-040424","article-title":"DNA replication stress as a hallmark of cancer","volume":"10","author":"Macheret","year":"2015","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.cell.2026.03.035_bib21","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.pharmthera.2018.03.005","article-title":"Targeting the replication stress response in cancer","volume":"188","author":"Forment","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.cell.2026.03.035_bib22","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.coph.2008.06.016","article-title":"Targeted therapy for cancer using PARP inhibitors","volume":"8","author":"Lord","year":"2008","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.cell.2026.03.035_bib23","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: Synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.cell.2026.03.035_bib24","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41571-024-00966-z","article-title":"Synthetic lethal strategies for the development of cancer therapeutics","volume":"22","author":"Ngoi","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.cell.2026.03.035_bib25","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1158\/1078-0432.CCR-18-0968","article-title":"PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers","volume":"25","author":"Pili\u00e9","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cell.2026.03.035_bib26","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.cell.2026.03.035_bib27","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.cell.2026.03.035_bib28","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers","volume":"361","author":"Fong","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cell.2026.03.035_bib29","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1097\/PPO.0000000000000556","article-title":"Development of Next-Generation Poly(ADP-Ribose) Polymerase 1-Selective Inhibitors","volume":"27","author":"Ngoi","year":"2021","journal-title":"Cancer J."},{"key":"10.1016\/j.cell.2026.03.035_bib30","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cell.2026.03.035_bib31","doi-asserted-by":"crossref","DOI":"10.1158\/1557-3265.SABCS24-GS1-09","article-title":"A phase 3, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients w\/ germline BRCA1 & BRCA2 pathogenic variants & highrisk HER2-negative primary breast cancer","volume":"31","author":"Garber","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cell.2026.03.035_bib32","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.cell.2026.03.035_bib33","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cell.2026.03.035_bib34","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer","volume":"381","author":"Golan","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cell.2026.03.035_bib35","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1200\/JCO.23.00339","article-title":"Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and\/or BRCA2 in the PROfound Trial","volume":"42","author":"Mateo","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cell.2026.03.035_bib36","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1136\/ijgc-2023-004995","article-title":"Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1\/ENGOT-ov25 trial","volume":"34","author":"Lorusso","year":"2024","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.cell.2026.03.035_bib37","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1200\/JCO.23.02132","article-title":"Durvalumab Plus Carboplatin\/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial","volume":"42","author":"Westin","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cell.2026.03.035_bib38","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.annonc.2024.02.006","article-title":"Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer","volume":"35","author":"Bogani","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.cell.2026.03.035_bib39","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1470-2045(16)30559-9","article-title":"Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial","volume":"18","author":"Swisher","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cell.2026.03.035_bib40","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.cell.2026.03.035_bib41","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.eururo.2023.05.021","article-title":"Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study","volume":"84","author":"Abida","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.cell.2026.03.035_bib42","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJMoa2214676","article-title":"Rucaparib or Physician\u2019s Choice in Metastatic Prostate Cancer","volume":"388","author":"Fizazi","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cell.2026.03.035_bib43","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cell.2026.03.035_bib44","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer","volume":"381","author":"Gonzalez-Martin","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cell.2026.03.035_bib45","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/S1470-2045(19)30029-4","article-title":"Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial","volume":"20","author":"Moore","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cell.2026.03.035_bib46","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation","volume":"379","author":"Litton","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cell.2026.03.035_bib47","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","article-title":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Agarwal","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.cell.2026.03.035_bib48","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2022-CT007","article-title":"First in class, first in human trial of the next generation PARP1-selective inhibitor AZD5305 in patients (pts) with BRCA1\/2, PALB2 or RAD51C\/D mutations","volume":"82","author":"Yap","year":"2022","journal-title":"Cancer Res"},{"key":"10.1016\/j.cell.2026.03.035_bib49","volume":"43","author":"Azad","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cell.2026.03.035_bib50","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1158\/1078-0432.CCR-23-2094","article-title":"Preclinical Characterization of AZD9574, a Blood-Brain Barrier Penetrant Inhibitor of PARP1","volume":"30","author":"Staniszewska","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cell.2026.03.035_bib51","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1200\/JCO.2025.43.16_suppl.3122","article-title":"Safety and efficacy of EIK1003, a selective PARP1 inhibitor, as monotherapy in participants with advanced solid tumors","volume":"43","author":"Rasco","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cell.2026.03.035_bib52","doi-asserted-by":"crossref","first-page":"5725","DOI":"10.1158\/1538-7445.AM2025-5725","article-title":"Abstract 5725: The potent and selective PARP1 inhibitor and trapper SNV1521 exhibits combination activity with targeted and chemotherapeutics","volume":"85","author":"Gao","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.cell.2026.03.035_bib53","doi-asserted-by":"crossref","first-page":"S565","DOI":"10.1016\/j.annonc.2025.08.1492","article-title":"923MO First results from a phase I trial of SNV1521, a next generation, CNS-penetrant, PARP1-selective inhibitor in patients (pts) with molecularly selected advanced solid tumors","volume":"36","author":"Lorusso","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.cell.2026.03.035_bib54","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1158\/1538-7445.AM2025-1171","article-title":"M9466 (HRS-1167): A highly potent and selective PARP1 inhibitor with DNA trapping activity, monotherapy antitumor activity and synergistic potential with DDR inhibitors and chemotherapies","volume":"85","author":"Dahmen","year":"2025","journal-title":"Cancer Res"},{"key":"10.1016\/j.cell.2026.03.035_bib55","doi-asserted-by":"crossref","first-page":"5213","DOI":"10.1158\/1078-0432.CCR-21-1032","article-title":"Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study","volume":"27","author":"Yap","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cell.2026.03.035_bib56","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.annonc.2021.10.009","article-title":"Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced\/metastatic melanoma who have failed prior anti-PD-1 therapy","volume":"33","author":"Kim","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.cell.2026.03.035_bib57","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1093\/jnci\/djae098","article-title":"Ataxia telangiectasia and Rad3-related (ATR) inhibitor camonsertib dose optimization in patients with biomarker-selected advanced solid tumors (TRESR study)","volume":"116","author":"Fontana","year":"2024","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.cell.2026.03.035_bib58","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/s41416-023-02436-2","article-title":"A phase I study of ATR inhibitor gartisertib (M4344) as a single agent and in combination with carboplatin in patients with advanced solid tumours","volume":"130","author":"Burris","year":"2024","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cell.2026.03.035_bib59","article-title":"An open-label, single-arm, dose escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of the ATR inhibitor SC0245 in advanced solid malignancies","volume":"42","author":"Sun","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cell.2026.03.035_bib60","doi-asserted-by":"crossref","first-page":"8102","DOI":"10.1200\/JCO.2024.42.16_suppl.8102","article-title":"An open-label, multicenter, phase Ib\/II study of the ATR inhibitor SC0245 in combination with irinotecan in patients with relapsed and refractory extensive stage small cell lung cancer (ES-SCLC)","volume":"42","author":"Huang","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cell.2026.03.035_bib61","doi-asserted-by":"crossref","first-page":"S475","DOI":"10.1016\/j.annonc.2023.09.1866","article-title":"First results from the phase I trial of the ATR inhibitor, ART0380, in advanced solid tumors","volume":"34","author":"Moore","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.cell.2026.03.035_bib62","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1158\/1078-0432.CCR-23-2409","article-title":"First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors","volume":"30","author":"Yap","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cell.2026.03.035_bib63","doi-asserted-by":"crossref","first-page":"4203","DOI":"10.1158\/1538-7445.AM2025-4203","article-title":"Discovery and development of a potent and highly selective ATR inhibitor IMP9064","volume":"85","author":"Cai","year":"2025","journal-title":"Cancer Res"},{"key":"10.1016\/j.cell.2026.03.035_bib64","doi-asserted-by":"crossref","first-page":"S476","DOI":"10.1016\/j.annonc.2023.09.1867","article-title":"First-in-human study of ATR inhibitor IMP9064 monotherapy and in combination with PARP inhibitor senaparib in patients with advanced solid tumors","volume":"34","author":"Lin","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.cell.2026.03.035_bib65","doi-asserted-by":"crossref","first-page":"B010","DOI":"10.1158\/1535-7163.TARG-25-B010","article-title":"Updated data from ABOYA-119: A phase 1\/2a trial of ATRN-119, a novel macrocyclic ATR inhibitor, in patients with advanced solid tumors harboring DNA damage repair alterations","volume":"24","author":"Mahipal","year":"2025","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.cell.2026.03.035_bib66","doi-asserted-by":"crossref","first-page":"S604","DOI":"10.1016\/j.annonc.2025.08.1493","article-title":"924MO First data disclosure of the first-in-class DNA polymerase theta inhibitor, ART6043, as monotherapy and in combination with olaparib, in patients with molecularly-selected advanced solid tumors","volume":"36","author":"Yap","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.cell.2026.03.035_bib67","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1200\/JCO-24-01606","article-title":"ADAGIO: A Phase IIb, Open-Label, Single-Arm, Multicenter Study Assessing the Efficacy and Safety of Adavosertib (AZD1775) as Treatment for Recurrent or Persistent Uterine Serous Carcinoma","volume":"43","author":"Liu","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cell.2026.03.035_bib68","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.3120","article-title":"Results of a phase 1, dose-finding study of Debio 0123 as monotherapy in adult patients with advanced solid tumors: Safety, pharmacokinetic, and preliminary antitumor activity data","volume":"42","author":"Papadopoulos","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cell.2026.03.035_bib69","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.8098","article-title":"Debio 0123, a highly selective WEE1 inhibitor, in combination with carboplatin (C) and etoposide (E), in patients (pts) with recurrent small cell lung cancer (SCLC): Determination of recommended dose (RD) from a phase 1 escalation","volume":"43","author":"Gambardella","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cell.2026.03.035_bib72","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-25-1648","article-title":"A First-in-Human Study of ATM Inhibitor Lartesertib as Monotherapy in Patients with Advanced Solid Tumors","volume":"31","author":"Siu","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cell.2026.03.035_bib73","doi-asserted-by":"crossref","first-page":"eaat1719","DOI":"10.1126\/sciadv.aat1719","article-title":"The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models","volume":"4","author":"Durant","year":"2018","journal-title":"Sci Adv"},{"key":"10.1016\/j.cell.2026.03.035_bib74","doi-asserted-by":"crossref","first-page":"S119","DOI":"10.1016\/j.ijrobp.2024.07.217","article-title":"Safety and Preliminary Efficacy of AZD1390 + Radiation Therapy for Glioblastoma","volume":"120","author":"Yang","year":"2024","journal-title":"Int. J. Radiat. Oncol. Biol."},{"key":"10.1016\/j.cell.2026.03.035_bib75","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1093\/neuonc\/noaf102","article-title":"The novel brain penetrant ataxia-telangiectasia mutated inhibitor WSD0628 provides robust radiosensitization of brain tumor patient-derived xenografts","volume":"27","author":"Xue","year":"2025","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.cell.2026.03.035_bib76","doi-asserted-by":"crossref","first-page":"LB181","DOI":"10.1158\/1538-7445.AM2024-LB181","article-title":"First disclosure of XRD-0394, a novel dual ATM\/DNA-PK inhibitor, that potently radiosensitizes and potentiates PARP and topoisomerase inhibitors","volume":"84","author":"Gilmer","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.cell.2026.03.035_bib77","doi-asserted-by":"crossref","first-page":"CT016","DOI":"10.1158\/1538-7445.AM2025-CT016","article-title":"Abstract CT016: First-in-human (FIH) phase 1 trial of the oral first-in-class covalent Werner helicase (WRN) inhibitor RO7589831 in patients with microsatellite instable (MSI) and\/or mismatch repair deficient (dMMR) advanced solid tumors","volume":"85","author":"Yap","year":"2025","journal-title":"Cancer Res"},{"key":"10.1016\/j.cell.2026.03.035_bib78","doi-asserted-by":"crossref","first-page":"S605","DOI":"10.1016\/j.annonc.2025.08.1494","volume":"36","author":"Foote","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.cell.2026.03.035_bib79","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1200\/JCO.2024.42.16_suppl.3005","volume":"42","author":"Yap","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cell.2026.03.035_bib80","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/nrc1529","article-title":"Timeline: Chemotherapy and the war on cancer","volume":"5","author":"Chabner","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.cell.2026.03.035_bib81","doi-asserted-by":"crossref","first-page":"8643","DOI":"10.1158\/0008-5472.CAN-07-6611","article-title":"A history of cancer chemotherapy","volume":"68","author":"DeVita","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.cell.2026.03.035_bib82","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0960-9822(99)80118-3","article-title":"Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours","volume":"9","author":"K\u00f6berle","year":"1999","journal-title":"Curr. Biol."},{"key":"10.1016\/j.cell.2026.03.035_bib83","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nrc2946","article-title":"The genesis and evolution of high-grade serous ovarian cancer","volume":"10","author":"Bowtell","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.cell.2026.03.035_bib84","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1146\/annurev.bi.58.070189.002031","article-title":"DNA topoisomerase poisons as antitumor drugs","volume":"58","author":"Liu","year":"1989","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.cell.2026.03.035_bib85","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/nrc2607","article-title":"Targeting DNA topoisomerase II in cancer chemotherapy","volume":"9","author":"Nitiss","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.cell.2026.03.035_bib86","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/nrc1977","article-title":"Topoisomerase I inhibitors: camptothecins and beyond","volume":"6","author":"Pommier","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.cell.2026.03.035_bib87","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nrm.2016.111","article-title":"Roles of eukaryotic topoisomerases in transcription, replication and genomic stability","volume":"17","author":"Pommier","year":"2016","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.cell.2026.03.035_bib88","first-page":"575","article-title":"Antimetabolites in Cancer Treatment: Targeting Cellular Proliferation Pathways","volume":"9","author":"Sabalic","year":"2024","journal-title":"J. Cancer Sci. Res."},{"key":"10.1016\/j.cell.2026.03.035_bib89","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJM194806032382301","article-title":"Temporary Remissions in Acute Leukemia in Children Produced by Folic Acid Antagonist, 4-Aminopteroyl-Glutamic Acid","volume":"238","author":"Farber","year":"1948","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cell.2026.03.035_bib90","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1056\/NEJM198311033091805","article-title":"The Pharmacology and Clinical Use of Methotrexate","volume":"309","author":"Jolivet","year":"1983","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cell.2026.03.035_bib91","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrc1074","article-title":"5-fluorouracil: mechanisms of action and clinical strategies","volume":"3","author":"Longley","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.cell.2026.03.035_bib92","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1517\/14796694.1.1.7","article-title":"Role of gemcitabine in cancer therapy","volume":"1","author":"Toschi","year":"2005","journal-title":"Future Oncol."},{"key":"10.1016\/j.cell.2026.03.035_bib93","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1038\/onc.2011.30","article-title":"Mitosis as an anti-cancer target","volume":"30","author":"Janssen","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.cell.2026.03.035_bib94","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nrc1317","article-title":"Microtubules as a target for anticancer drugs","volume":"4","author":"Jordan","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.cell.2026.03.035_bib95","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1091\/mbc.e14-04-0916","article-title":"How Taxol\/paclitaxel kills cancer cells","volume":"25","author":"Weaver","year":"2014","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.cell.2026.03.035_bib96","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1056\/NEJM199504063321401","article-title":"Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil in Node-Positive Breast Cancer \u2014 The Results of 20 Years of Follow-up","volume":"332","author":"Bonadonna","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cell.2026.03.035_bib97","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrc2394","article-title":"Paul Ehrlich\u2019s magic bullet concept: 100 years of progress","volume":"8","author":"Strebhardt","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.cell.2026.03.035_bib98","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/abt\/tby002","article-title":"Enhancing antibody-dependent cell-mediated cytotoxicity: a strategy for improving antibody-based immunotherapy","volume":"1","author":"Zahavi","year":"2018","journal-title":"Antibody Ther."},{"key":"10.1016\/j.cell.2026.03.035_bib99","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1200\/JCO.1999.17.2.478","article-title":"Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer","volume":"17","author":"Tolcher","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cell.2026.03.035_bib100","first-page":"4154","article-title":"Phase I clinical comparative study of monoclonal antibody KS1\/4 and KS1\/4-methotrexate immunconjugate in patients with non-small cell lung carcinoma","volume":"50","author":"Elias","year":"1990","journal-title":"Cancer Res."},{"key":"10.1016\/j.cell.2026.03.035_bib101","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13045-025-01704-3","article-title":"Antibody\u2013Drug Conjugates (ADCs): current and future biopharmaceuticals","volume":"18","author":"Wang","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.cell.2026.03.035_bib102","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/256495a0","article-title":"Continuous cultures of fused cells secreting antibody of predefined specificity","volume":"256","author":"K\u00f6hler","year":"1975","journal-title":"Nature"},{"key":"10.1016\/j.cell.2026.03.035_bib103","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/S1471-4892(03)00083-3","article-title":"Antibody-targeted chemotherapy with immunoconjugates of calicheamicin","volume":"3","author":"Damle","year":"2003","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.cell.2026.03.035_bib104","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.2174\/1381612003398564","article-title":"Understanding and Exploiting Natures Chemical Arsenal: The Past, Present and Future of Calicheamicin Research","volume":"6","author":"Thorson","year":"2000","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.cell.2026.03.035_bib105","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1021\/bc010021y","article-title":"Gemtuzumab Ozogamicin, A Potent and Selective Anti-CD33 Antibody\u2212Calicheamicin Conjugate for Treatment of Acute Myeloid Leukemia","volume":"13","author":"Hamann","year":"2002","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.cell.2026.03.035_bib106","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-28533-4","article-title":"Pre-clinical pharmacology and mechanism of action of SG3199, the pyrrolobenzodiazepine (PBD) dimer warhead component of antibody-drug conjugate (ADC) payload tesirine","volume":"8","author":"Hartley","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cell.2026.03.035_bib107","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13045-023-01519-0","article-title":"Considerations for the design of antibody drug conjugates (ADCs) for clinical development: lessons learned","volume":"16","author":"L\u00f3pez De S\u00e1","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.cell.2026.03.035_bib108","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/00001622-200111000-00016","article-title":"Mylotarg: antibody-targeted chemotherapy comes of age","volume":"13","author":"Sievers","year":"2001","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.cell.2026.03.035_bib109","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1007\/s40265-017-0802-5","article-title":"Inotuzumab Ozogamicin: First Global Approval","volume":"77","author":"Lamb","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.cell.2026.03.035_bib110","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.3324\/haematol.2023.284197","article-title":"Targeting CD19-positive lymphomas with the antibodydrug conjugate loncastuximab tesirine: preclinical evidence of activity as a single agent and in combination therapy","volume":"109","author":"Tarantelli","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.cell.2026.03.035_bib111","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1126\/science.3240341","article-title":"Calicheamicin gamma 1I: an antitumor antibiotic that cleaves double-stranded DNA site specifically","volume":"240","author":"Zein","year":"1988","journal-title":"Science"},{"key":"10.1016\/j.cell.2026.03.035_bib112","first-page":"429","article-title":"Initial clinical trials of maytansine, an antitumor plant alkaloid","volume":"62","author":"Chabner","year":"1978","journal-title":"Cancer Treat. Rep."},{"key":"10.1016\/j.cell.2026.03.035_bib113","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1155\/2004\/924913","article-title":"Phase II Trial of Dolastatin-10, a Novel Anti-Tubulin Agent, in Metastatic Soft Tissue Sarcomas","volume":"8","author":"Von Mehren","year":"2004","journal-title":"Sarcoma"},{"key":"10.1016\/j.cell.2026.03.035_bib114","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1021\/acs.jnatprod.1c01135","article-title":"Discovery and Development of Dolastatin 10-Derived Antibody Drug Conjugate Anticancer Drugs","volume":"85","author":"Singh","year":"2022","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.cell.2026.03.035_bib115","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/nbt.2289","article-title":"The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma","volume":"30","author":"Senter","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.cell.2026.03.035_bib116","doi-asserted-by":"crossref","first-page":"5131","DOI":"10.1158\/1078-0432.CCR-15-0670","article-title":"Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2\u2013SN-38 Antibody Conjugate (Sacituzumab Govitecan)","volume":"21","author":"Sharkey","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cell.2026.03.035_bib117","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cell.2026.03.035_bib118","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2026.189550","article-title":"Innovations in HER2-targeted therapy: A comprehensive review of trastuzumab deruxtecan","volume":"1881","author":"Xie","year":"2026","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.cell.2026.03.035_bib119","doi-asserted-by":"crossref","first-page":"4774","DOI":"10.3390\/ijms22094774","article-title":"Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors","volume":"22","author":"Indini","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cell.2026.03.035_bib120","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2230618","article-title":"Therapeutic index improvement of antibody-drug conjugates","volume":"15","author":"Gerber","year":"2023","journal-title":"mAbs"},{"key":"10.1016\/j.cell.2026.03.035_bib121","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1158\/1078-0432.CCR-22-2630","article-title":"Design and Preclinical Evaluation of a Novel B7-H4\u2013Directed Antibody\u2013Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305","volume":"29","author":"Kinneer","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cell.2026.03.035_bib122","first-page":"161","article-title":"Combined inhibition of PARP and ATR synergistically potentiates the antitumor activity of HER2-targeting antibody-drug conjugate in HER2-positive cancers","volume":"13","author":"Li","year":"2023","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.cell.2026.03.035_bib123","article-title":"Phase Ib SEASTAR Study: Combining Rucaparib and Sacituzumab Govitecan in Patients With Cancer With or Without Mutations in Homologous Recombination Repair Genes","volume":"6","author":"Yap","year":"2022","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.cell.2026.03.035_bib124","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1158\/1078-0432.CCR-24-0428","article-title":"Antibody\u2013Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1\/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer","volume":"30","author":"Bardia","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cell.2026.03.035_bib125","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1158\/2159-8290.CD-11-0320","article-title":"Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1","volume":"2","author":"Aarts","year":"2012","journal-title":"Cancer Discov."},{"key":"10.1016\/j.cell.2026.03.035_bib126","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.radonc.2017.09.043","article-title":"ATR\/CHK1 inhibitors and cancer therapy","volume":"126","author":"Qiu","year":"2018","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.cell.2026.03.035_bib127","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1186\/s12964-024-01893-3","article-title":"Immunomodulatory effects of trastuzumab deruxtecan through the cGAS-STING pathway in gastric cancer cells","volume":"22","author":"Oh","year":"2024","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.cell.2026.03.035_bib128","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009710","article-title":"Novel bispecific antibody-drug conjugate targeting PD-L1 and B7-H3 enhances antitumor efficacy and promotes immune-mediated antitumor responses","volume":"12","author":"Dong","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.cell.2026.03.035_bib129","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cell.2026.03.035_bib130","doi-asserted-by":"crossref","first-page":"S1485","DOI":"10.1016\/j.annonc.2025.08.3686","article-title":"Abstract 3072MO. Datopotamab deruxtecan (Dato-DXd) + rilvegostomig (rilve) in patients (pts) with locally advanced or metastatic urothelial cancer (a\/mUC): results from the phase 2 TROPION-PanTumor03 study","volume":"36","author":"Rha","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.cell.2026.03.035_bib131","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s40265-013-0050-2","article-title":"Trastuzumab emtansine: first global approval","volume":"73","author":"Ballantyne","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.cell.2026.03.035_bib132","doi-asserted-by":"crossref","first-page":"9280","DOI":"10.1158\/0008-5472.CAN-08-1776","article-title":"Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate","volume":"68","author":"Lewis Phillips","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.cell.2026.03.035_bib133","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1007\/s10120-021-01196-3","article-title":"Discovery and development of trastuzumab deruxtecan and safety management for patients with HER2-positive gastric cancer","volume":"24","author":"Shitara","year":"2021","journal-title":"Gastric Cancer: Off. J. Int. Gastric Cancer Assoc. Jpn. Gastric Cancer Assoc."},{"key":"10.1016\/j.cell.2026.03.035_bib134","doi-asserted-by":"crossref","first-page":"5268","DOI":"10.1091\/mbc.e04-07-0591","article-title":"Endocytosis and Sorting of ErbB2 and the Site of Action of Cancer Therapeutics Trastuzumab and Geldanamycin","volume":"15","author":"Austin","year":"2004","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.cell.2026.03.035_bib135","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0140-6736(22)02420-5","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial","volume":"401","author":"Hurvitz","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.cell.2026.03.035_bib136","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1118\/1.2400621","article-title":"Depth absorbed dose and LET distributions of therapeutic 1H, 4He, 7Li, and 12C beams","volume":"34","author":"Kempe","year":"2007","journal-title":"Med. Phys."},{"key":"10.1016\/j.cell.2026.03.035_bib137","article-title":"Proton versus photon radiation therapy: A clinical review","volume":"13","author":"Chen","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.cell.2026.03.035_bib138","first-page":"474","article-title":"Radioactive iodine in the study of thyroid physiology; the use of radioactive iodine therapy in Graves\u2019 disease","volume":"54","author":"Hertz","year":"1946","journal-title":"West. J. Surg. Obstet. Gynecol."},{"key":"10.1016\/j.cell.2026.03.035_bib139","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1001\/jama.1946.02870490016004","article-title":"Radioactive iodine therapy; effect on functioning metastases of adenocarcinoma of the thyroid","volume":"132","author":"Seidlin","year":"1946","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.cell.2026.03.035_bib140","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/s41571-022-00652-y","article-title":"Radiotheranostics in oncology: current challenges and emerging opportunities","volume":"19","author":"Bodei","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.cell.2026.03.035_bib141","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","article-title":"177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial","volume":"404","author":"Morris","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.cell.2026.03.035_bib142","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1007\/s00259-025-07103-7","article-title":"Radiotheranostic landscape: A review of clinical and preclinical development","volume":"52","author":"Tran","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.cell.2026.03.035_bib145","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1007\/s11307-023-01857-y","article-title":"Alpha Particle-Emitting Radiopharmaceuticals as Cancer Therapy: Biological Basis, Current Status, and Future Outlook for Therapeutics Discovery","volume":"25","author":"Coll","year":"2023","journal-title":"Mol. Imaging Biol."},{"key":"10.1016\/j.cell.2026.03.035_bib146","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1093\/carcin\/20.5.905","article-title":"A study of endonuclease III-sensitive sites in irradiated DNA: detection of \u03b1-particle-induced oxidative damage","volume":"20","author":"Prise","year":"1999","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.cell.2026.03.035_bib147","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.7150\/thno.124671","article-title":"Contemporary opportunities and potential of Auger electron-emitting theranostics","volume":"16","author":"Lee","year":"2026","journal-title":"Theranostics"},{"key":"10.1016\/j.cell.2026.03.035_bib148","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.7150\/thno.96403","article-title":"Actinium-225 targeted alpha particle therapy for prostate cancer","volume":"14","author":"Bidkar","year":"2024","journal-title":"Theranostics"},{"key":"10.1016\/j.cell.2026.03.035_bib149","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.addr.2008.04.009","article-title":"Realizing the potential of the Actinium-225 radionuclide generator in targeted alpha particle therapy applications","volume":"60","author":"Miederer","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.cell.2026.03.035_bib150","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s41181-024-00239-1","article-title":"Implementing Ac-225 labelled radiopharmaceuticals: practical considerations and (pre-)clinical perspectives","volume":"9","author":"Hooijman","year":"2024","journal-title":"EJNMMI Radiopharm. Chem."},{"key":"10.1016\/j.cell.2026.03.035_bib151","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41573-020-0073-9","article-title":"Radiopharmaceutical therapy in cancer: clinical advances and challenges","volume":"19","author":"Sgouros","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.cell.2026.03.035_bib152","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.37349\/etat.2024.00264","article-title":"Anticancer peptides as novel immunomodulatory therapeutic candidates for cancer treatment","volume":"5","author":"Sood","year":"2024","journal-title":"Explor. Target Antitumor Ther."},{"key":"10.1016\/j.cell.2026.03.035_bib153","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1158\/1078-0432.CCR-24-3571","article-title":"Myt1 Kinase: An Emerging Cell-Cycle Regulator for Cancer Therapeutics","volume":"31","author":"Lang","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cell.2026.03.035_bib154","doi-asserted-by":"crossref","first-page":"7816","DOI":"10.1038\/sj.onc.1210879","article-title":"Targeted cancer therapies based on the inhibition of DNA strand break repair","volume":"26","author":"O\u2019Connor","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.cell.2026.03.035_bib155","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1158\/1541-7786.MCR-14-0240","article-title":"A Synthetic Lethal Screen Reveals Enhanced Sensitivity to ATR Inhibitor Treatment in Mantle Cell Lymphoma with ATM Loss-of-Function","volume":"13","author":"Menezes","year":"2015","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.cell.2026.03.035_bib156","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/s41586-019-1102-x","article-title":"WRN helicase is a synthetic lethal target in microsatellite unstable cancers","volume":"568","author":"Chan","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.cell.2026.03.035_bib157","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.43333","article-title":"Werner syndrome helicase is a selective vulnerability of microsatellite instability-high tumor cells","volume":"8","author":"Lieb","year":"2019","journal-title":"eLife"},{"key":"10.1016\/j.cell.2026.03.035_bib158","doi-asserted-by":"crossref","first-page":"E5940","DOI":"10.1073\/pnas.1708065114","article-title":"FANCM, BRCA1, and BLM cooperatively resolve the replication stress at the ALT telomeres","volume":"114","author":"Pan","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.cell.2026.03.035_bib159","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-10179-z","article-title":"FANCM limits ALT activity by restricting telomeric replication stress induced by deregulated BLM and R-loops","volume":"10","author":"Silva","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cell.2026.03.035_bib160","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1200\/EDBK_238473","article-title":"The DNA Damaging Revolution: PARP Inhibitors and Beyond","volume":"39","author":"Yap","year":"2019","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"10.1016\/j.cell.2026.03.035_bib161","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0140-6736(10)60892-6","article-title":"Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial","volume":"376","author":"Tutt","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.cell.2026.03.035_bib162","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3390\/cancers10120487","article-title":"Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors","volume":"10","author":"Faraoni","year":"2018","journal-title":"Cancers"},{"key":"10.1016\/j.cell.2026.03.035_bib163","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1101\/gad.1301205","article-title":"Functional uncoupling of MCM helicase and DNA polymerase activities activates the ATR-dependent checkpoint","volume":"19","author":"Byun","year":"2005","journal-title":"Genes Dev."},{"key":"10.1016\/j.cell.2026.03.035_bib164","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/ncb2897","article-title":"Causes and consequences of replication stress","volume":"16","author":"Zeman","year":"2014","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.cell.2026.03.035_bib165","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.cell.2011.03.044","article-title":"Nucleotide deficiency promotes genomic instability in early stages of cancer development","volume":"145","author":"Bester","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.cell.2026.03.035_bib166","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S1097-2765(02)00520-8","article-title":"c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability","volume":"9","author":"Vafa","year":"2002","journal-title":"Mol. Cell"},{"key":"10.1016\/j.cell.2026.03.035_bib167","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.molcel.2015.07.029","article-title":"Distinct but Concerted Roles of ATR, DNA-PK, and Chk1 in Countering Replication Stress during S Phase","volume":"59","author":"Buisson","year":"2015","journal-title":"Mol. Cell"},{"key":"10.1016\/j.cell.2026.03.035_bib168","doi-asserted-by":"crossref","first-page":"4226","DOI":"10.1128\/MCB.00412-12","article-title":"Cyclin-dependent kinase suppression by WEE1 kinase protects the genome through control of replication initiation and nucleotide consumption","volume":"32","author":"Beck","year":"2012","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.cell.2026.03.035_bib169","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/emboj\/16.3.545","article-title":"Chk1 is a wee1 kinase in the G2 DNA damage checkpoint inhibiting cdc2 by Y15 phosphorylation","volume":"16","author":"O\u2019Connell","year":"1997","journal-title":"EMBO J."},{"key":"10.1016\/j.cell.2026.03.035_bib170","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.4161\/cc.26062","article-title":"Wee1 kinase as a target for cancer therapy","volume":"12","author":"Do","year":"2013","journal-title":"Cell Cycle (Georget. Tex.)"},{"key":"10.1016\/j.cell.2026.03.035_bib171","doi-asserted-by":"crossref","first-page":"4536","DOI":"10.1158\/1078-0432.CCR-22-0568","article-title":"Identification of a molecularly-defined subset of breast and ovarian cancer models that respond to WEE1 or ATR inhibition, overcoming PARP inhibitor resistance","volume":"28","author":"Serra","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cell.2026.03.035_bib172","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.1158\/1078-0432.CCR-21-0329","article-title":"Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors","volume":"27","author":"Takebe","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cell.2026.03.035_bib173","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.29065","article-title":"A phase 1 study of prexasertib (LY2606368), a CHK1\/2 inhibitor, in pediatric patients with recurrent or refractory solid tumors, including CNS tumors: A report from the Children\u2019s Oncology Group Pediatric Early Phase Clinical Trials Network (ADVL1515)","volume":"68","author":"Cash","year":"2021","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.cell.2026.03.035_bib174","doi-asserted-by":"crossref","first-page":"22300","DOI":"10.1074\/jbc.272.35.22300","article-title":"Human Myt1 Is a Cell Cycle-regulated Kinase That Inhibits Cdc2 but Not Cdk2 Activity","volume":"272","author":"Booher","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cell.2026.03.035_bib175","doi-asserted-by":"crossref","first-page":"4420","DOI":"10.1158\/1538-7445.AM2013-4420","article-title":"Abstract 4420: Generating preclinical models to assess bone marrow toxicity induced by the PARP inhibitor olaparib in combination with chemotherapy","volume":"73","author":"O\u2019Connor","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.cell.2026.03.035_bib176","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/annonc\/mdw697","article-title":"PARP inhibitor and chemotherapy combination trials for the treatment of advanced malignancies: does a development pathway forward exist?","volume":"28","author":"Matulonis","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.cell.2026.03.035_bib177","doi-asserted-by":"crossref","first-page":"6400","DOI":"10.1158\/1078-0432.CCR-17-0703","article-title":"Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors","volume":"23","author":"Dhawan","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cell.2026.03.035_bib178","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41523-022-00411-3","article-title":"PARP inhibition in breast cancer: progress made and future hopes","volume":"8","author":"Tung","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.cell.2026.03.035_bib179","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-59151-0","article-title":"Neoadjuvant PARP inhibitor scheduling in BRCA1 and BRCA2 related breast cancer: PARTNER, a randomized phase II\/III trial","volume":"16","author":"Abraham","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cell.2026.03.035_bib180","article-title":"CRLX101, an investigational camptothecin-containing nanoparticle-drug conjugate, combined with DDR agents provides a novel approach to increasing therapeutic index","volume":"15","author":"Oplustil O\u2019Connor","year":"2016","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.cell.2026.03.035_bib181","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-64509-5","article-title":"Tumor-targeted top1 inhibitor delivery with optimized parp inhibition in advanced solid tumors: a phase i trial of gapped scheduling","volume":"16","author":"Thomas","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cell.2026.03.035_bib182","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/CCO.0000000000000867","article-title":"Targeting the DNA damage response beyond poly(ADP-ribose) polymerase inhibitors: Novel agents and rational combinations","volume":"34","author":"Ngoi","year":"2022","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.cell.2026.03.035_bib183","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/s41416-024-02745-0","article-title":"ATR, CHK1 and WEE1 inhibitors cause homologous recombination repair deficiency to induce synthetic lethality with PARP inhibitors","volume":"131","author":"Smith","year":"2024","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.cell.2026.03.035_bib184","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1158\/1078-0432.CCR-22-2444","article-title":"Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) trial in acquired PARP inhibitor-resistant homologous recombination-deficient ovarian cancer","volume":"29","author":"Wethington","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cell.2026.03.035_bib185","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200043","article-title":"Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer","volume":"1","author":"Clarke","year":"2022","journal-title":"NEJM Evid."},{"key":"10.1016\/j.cell.2026.03.035_bib186","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41591-023-02704-x","article-title":"First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial","volume":"30","author":"Fizazi","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.cell.2026.03.035_bib187","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cell.2026.03.035_bib188","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1462496","article-title":"Genomic instability as a driver and suppressor of anti-tumor immunity","volume":"15","author":"Requesens","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cell.2026.03.035_bib189","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s13073-025-01509-6","article-title":"Genome instability and crosstalk with the immune response","volume":"17","author":"Chabanon","year":"2025","journal-title":"Genome Med."},{"key":"10.1016\/j.cell.2026.03.035_bib190","doi-asserted-by":"crossref","first-page":"5309","DOI":"10.1016\/j.cell.2021.09.020","article-title":"Hallmarks of response, resistance, and toxicity to immune checkpoint blockade","volume":"184","author":"Morad","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.cell.2026.03.035_bib191","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001460","article-title":"Rethinking immune checkpoint blockade: \u2018Beyond the T cell\u2019","volume":"9","author":"Liu","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.cell.2026.03.035_bib192","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s40364-025-00814-x","article-title":"The distinct landscape of tumor immune microenvironment in homologous recombination deficient cancers","volume":"13","author":"Xu","year":"2025","journal-title":"Biomark. Res."},{"key":"10.1016\/j.cell.2026.03.035_bib193","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.cytogfr.2025.06.002","article-title":"Metabolic Regulation of cGAS-STING Signaling in the Tumor Microenvironment: Dual Immune Roles and Therapeutic Implications","volume":"85","author":"Wu","year":"2025","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.cell.2026.03.035_bib194","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.ccell.2025.02.014","article-title":"Targeting tumor monocyte-intrinsic PD-L1 by rewiring STING signaling and enhancing STING agonist therapy","volume":"43","author":"Song","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cell.2026.03.035_bib195","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-017-01883-9","article-title":"DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells","volume":"8","author":"Sato","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cell.2026.03.035_bib196","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20210789","article-title":"WEE1 inhibition induces anti-tumor immunity by activating ERV and the dsRNA pathway","volume":"219","author":"Guo","year":"2022","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.cell.2026.03.035_bib197","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1097\/00007890-198710000-00018","article-title":"Induction of IL-2 receptor expression in vivo. Response to allogeneic cells","volume":"44","author":"Kroczek","year":"1987","journal-title":"Transplantation"},{"key":"10.1016\/j.cell.2026.03.035_bib198","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.bbrc.2015.05.083","article-title":"The PARP1 inhibitor BMN 673 exhibits immunoregulatory effects in a Brca1(-\/-) murine model of ovarian cancer","volume":"463","author":"Huang","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.cell.2026.03.035_bib199","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1158\/2159-8290.CD-18-1218","article-title":"PARP Inhibitor Efficacy Depends on CD8+ T-Cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer","volume":"9","author":"Pantelidou","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.cell.2026.03.035_bib200","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1158\/0008-5472.CAN-18-1003","article-title":"PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness","volume":"79","author":"Shen","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.cell.2026.03.035_bib201","article-title":"Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models","volume":"9","author":"Wang","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cell.2026.03.035_bib202","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41698-021-00232-w","article-title":"Multiomics analysis of serial PARP inhibitor treated metastatic TNBC inform on rational combination therapies","volume":"5","author":"Labrie","year":"2021","journal-title":"NPJ Precis. Oncol."},{"key":"10.1016\/j.cell.2026.03.035_bib203","article-title":"Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer","volume":"11","author":"F\u00e4rkkil\u00e4","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cell.2026.03.035_bib204","doi-asserted-by":"crossref","first-page":"6354","DOI":"10.1158\/1078-0432.CCR-21-1656","article-title":"Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer","volume":"27","author":"Westin","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cell.2026.03.035_bib205","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.imbio.2011.10.016","article-title":"Interferon-gamma-induced PD-L1 surface expression on human oral squamous carcinoma via PKD2 signal pathway","volume":"217","author":"Chen","year":"2012","journal-title":"Immunobiology"},{"key":"10.1016\/j.cell.2026.03.035_bib206","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.neo.2018.03.003","article-title":"Combined Inhibition of ATR and WEE1 as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer","volume":"20","author":"Jin","year":"2018","journal-title":"Neoplasia"},{"key":"10.1016\/j.cell.2026.03.035_bib207","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/0092-8674(93)80048-J","article-title":"Human wee1 maintains mitotic timing by protecting the nucleus from cytoplasmically activated Cdc2 kinase","volume":"74","author":"Heald","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.cell.2026.03.035_bib208","doi-asserted-by":"crossref","first-page":"305","DOI":"10.4161\/cbt.3.3.697","article-title":"Knockdown of Chk1, Wee1 and Myt1 by RNA interference abrogates G2 checkpoint and induces apoptosis","volume":"3","author":"Wang","year":"2004","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.cell.2026.03.035_bib209","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1158\/1535-7163.MCT-11-0469","article-title":"Targeting radiation-induced G(2) checkpoint activation with the Wee-1 inhibitor MK-1775 in glioblastoma cell lines","volume":"10","author":"Sarcar","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.cell.2026.03.035_bib210","article-title":"WEE1 inhibition targets cell cycle checkpoints for triple negative breast cancers to overcome cisplatin resistance","volume":"7","author":"Zheng","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cell.2026.03.035_bib211","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-45996-4","article-title":"The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment","volume":"15","author":"Hardaker","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cell.2026.03.035_bib212","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a028373","article-title":"The Role of Aneuploidy in Cancer Evolution","volume":"7","author":"Sansregret","year":"2017","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.cell.2026.03.035_bib213","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.cell.2018.08.027","article-title":"The Multifaceted Role of Chromosomal Instability in Cancer and Its Microenvironment","volume":"174","author":"Bakhoum","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.cell.2026.03.035_bib214","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.3003","article-title":"First-in-human study of PC14586, a small molecule structural corrector of Y220C mutant p53, in patients with advanced solid tumors harboring a TP53 Y220C mutation","volume":"40","author":"Dumbrava","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cell.2026.03.035_bib215","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-21447-2","article-title":"Chromosomally unstable tumor cells specifically require KIF18A for proliferation","volume":"12","author":"Marquis","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cell.2026.03.035_bib216","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS3181","article-title":"A phase I\/II, first-in-human study of VLS-1488, an oral KIF18A inhibitor, in patients with advanced cancer","volume":"42","author":"Gaillard","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cell.2026.03.035_bib217","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/s41586-020-2710-1","article-title":"TRIM37 controls cancer-specific vulnerability to PLK4 inhibition","volume":"585","author":"Meitinger","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.cell.2026.03.035_bib218","article-title":"DHX9 SUMOylation is required for the suppression of R-loop-associated genome instability","volume":"15","author":"Yang","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cell.2026.03.035_bib219","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1158\/0008-5472.CAN-24-0397","article-title":"A Potent, Selective, Small-Molecule Inhibitor of DHX9 Abrogates Proliferation of Microsatellite Instable Cancers with Deficient Mismatch Repair","volume":"85","author":"Castro","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.cell.2026.03.035_bib220","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/nature21356","article-title":"Extrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneity","volume":"543","author":"Turner","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.cell.2026.03.035_bib221","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1126\/science.1241328","article-title":"Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA","volume":"343","author":"Nathanson","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.cell.2026.03.035_bib222","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/s41586-024-08107-3","article-title":"Origins and impact of extrachromosomal DNA","volume":"635","author":"Bailey","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.cell.2026.03.035_bib223","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1158\/2159-8290.CD-25-0230","article-title":"A Guide to Extrachromosomal DNA: Cancer\u2019s Dynamic Circular Genome","volume":"15","author":"Weiser","year":"2025","journal-title":"Cancer Discov."},{"key":"10.1016\/j.cell.2026.03.035_bib224","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/s41588-020-0678-2","article-title":"Extrachromosomal DNA is associated with oncogene amplification and poor outcome across multiple cancers","volume":"52","author":"Kim","year":"2020","journal-title":"Nat. Genet."},{"key":"10.1016\/j.cell.2026.03.035_bib225","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1038\/s41588-022-01177-x","article-title":"The evolutionary dynamics of extrachromosomal DNA in human cancers","volume":"54","author":"Lange","year":"2022","journal-title":"Nat. Genet."},{"key":"10.1016\/j.cell.2026.03.035_bib226","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41586-024-07802-5","article-title":"Enhancing transcription\u2013replication conflict targets ecDNA-positive cancers","volume":"635","author":"Tang","year":"2024","journal-title":"Nature"}],"container-title":["Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0092867426003363?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0092867426003363?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T15:43:39Z","timestamp":1782488619000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0092867426003363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":222,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0092867426003363"],"URL":"https:\/\/doi.org\/10.1016\/j.cell.2026.03.035","relation":{},"ISSN":["0092-8674"],"issn-type":[{"value":"0092-8674","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting genomic instability in cancer","name":"articletitle","label":"Article Title"},{"value":"Cell","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cell.2026.03.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}